| Name | QNZ46 |
| Description | QNZ46 is a non-competitive antagonist of NMDA receptors, selectively targeting NR2C/NR2D subunits. |
| Kinase Assay | Biochemical filter-binding assays for detection of FGFR phosphorylation activities : Reaction mixtures contains 8 mM Tris-HCl (pH 7.5), 10 mmol/L HEPES, 5 mM dithiothreitol, 10 μM ATP, 0.5 μCi 33P-ATP, 10 mM MnCl2, 150 mM NaCl, 0.01% Triton X-100, 4% dimethyl sulfoxide, 0.05 mg/mL poly(Glu:Tyr) (4:1, average molecular weight of 20–50 kDa), and 7.5, 7.5, and 16 ng of FGFR1, FGFR3, and FGFR4, respectively, and are incubated at room temperature for 30 minutes followed by termination with 10% H3PO4. The reaction mixtures are transferred to 96-well MAFB filter plates that are washed 3 times with 0.5% H3PO4. After air-drying, the plates are read with a Trilux reader. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.43 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | QNZ-46 | Ionotropic glutamate receptors | inhibit | Inhibitor | iGluR | QNZ 46 | QNZ46 |
| Inhibitors Related | Mephenesin | Decanoic Acid | L-Glutamic acid | glycine | Halothane | L-Glutamic acid monosodium salt | Riluzole | D-Cycloserine | Piracetam | Linalool | O-Phospho-L-serine | Procaine hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Antidepressant Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
United States
